^
Association details:
| Biomarker: | KIT positive |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | opelkibart elmanitin (MGTA-117) (c-KIT-targeted antibody-drug conjugate, RNA polymerase 2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
874 Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study
Published date:
11/03/2022
Excerpt:
This is a multicenter, open-label study (NCT05223699). Adult participants (pts) are eligible who have a WHO-defined diagnosis of CD117+ R/R AML or MDS-EB...Preliminary data show in vivo stability of the ADC with rapid clearance from blood, robust binding of MGTA-117 on CD117+ cells, and early evidence of single-agent biological activity....The trial continues to advance, and progress is being made toward development of MGTA-117 as a myelodepletive conditioning agent for HSCT in AML/MDS and gene therapy indications.
DOI:
https://doi.org/10.1182/blood-2022-162406
Trial ID:
